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A B S T R A C T
Chronic kidney disease (CKD) is a common medical condition of ageing cats. In most cases the under-
lying aetiology is unknown, but themost frequently reported pathological diagnosis is renal tubulointerstitial
ﬁbrosis. Renal ﬁbrosis, characterised by extensive accumulation of extra-cellular matrix within the in-
terstitium, is thought to be the ﬁnal common pathway for all kidney diseases and is the pathological
lesion best correlated with function in both humans and cats. As a convergent pathway, renal ﬁbrosis
provides an ideal target for the treatment of CKD and knowledge of the underlying ﬁbrotic process is
essential for the future development of novel therapies. There are many mediators and mechanisms of
renal ﬁbrosis reported in the literature, of which only a few have been investigated in the cat. This article
reviews the process of renal ﬁbrosis and discusses the most commonly cited mediators and mecha-
nisms of progressive renal injury, with particular focus on the potential signiﬁcance to feline CKD.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Chronic kidney disease (CKD) is deﬁned as the presence of struc-
tural or functional abnormalities of one or both kidneys that have
been present for an extended period of time. CKD is common in cats,
one study reporting that 12% of all cats necropsied over a period
of 3 years were suffering from the condition (Taugner et al., 1996).
The prevalence of CKD also increases with age, with reported prev-
alence rates of 28% in cats over 12 years old (Bartlett et al., 2010)
and 31% in cats over 15 years old (Lulich et al., 1992).
The aetiology of feline CKD is heterogeneous and includes spe-
ciﬁc disease processes which initiate renal damage or dysfunction,
such as polycystic kidney disease, renal amyloidosis, renal dyspla-
sia and renal lymphoma (Reynolds and Lefebvre, 2013). However in
themajority of catswith CKD no inciting cause is identiﬁed. One study
of a referral population found pathological lesions of a speciﬁc renal
disease in 50% of cases (DiBartola et al., 1987), another in 33% of cases
(Minkus et al., 1994). A recent study with a large population from
ﬁrst opinion practices identiﬁed speciﬁc renal lesions in only 16% of
cats (Chakrabarti et al., 2013). Themajority of cats with CKD are found
to have non-speciﬁc renal lesions and the predominant morpholog-
ical diagnosis in these cases is chronic tubulointerstitial inﬂammation
and ﬁbrosis (DiBartola et al., 1987; Chakrabarti et al., 2013).
The underlying aetiology of CKD in the majority of cats, where
chronic tubulointerstitial ﬁbrosis is present, is not understood.
Various factors which may contribute to renal damage have been
proposed, including diet (Hughes et al., 2002), vaccination (Lappin
et al., 2006), and ageing (Lawler et al., 2006). Regardless of the ae-
tiology, the progressive nature of renal ﬁbrosis results in deterioration
of renal function independent of the initial renal insult. Renal
tubulointerstitial ﬁbrosis is recognised as the ﬁnal common pathway
for all kidney diseases in human patients regardless of aetiology
(Prunotto et al., 2011) and is the pathological lesion best corre-
lated with renal function in both humans (Risdon et al., 1968; Nath,
1992) and cats (Yabuki et al., 2010; Chakrabarti et al., 2013).
Despite ongoing research there is currently no effective treatment
that signiﬁcantly slows the progression of renal ﬁbrosis in humans or
in cats. Therefore,much attention is directed at identifying factorswhich
inﬂuence or drive the progression of ﬁbrosis in order to identify po-
tential therapeutic targets. The aim of this article is to provide a review
of the renal ﬁbrotic process and evaluate previous research published
on mediators and mechanisms of renal ﬁbrosis, with particular focus
on those investigated in cats, in order to provide updated information
for veterinary clinicians and pathologists.
Renal ﬁbrosis
In most cases of tissue damage, injured cells are replaced by cells
of the same type and/or ﬁbrous tissue after the resolution of the
inﬂammatory response. The kidney has an intrinsic capacity for
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self-repair after ischaemic or toxic insults that result in cell death
and can potentially recover completely after sustaining acute injury.
This repair occurs primarily through epithelial cell proliferation, and
it appears that an intact basement membrane plays an important
role by providing a scaffold along which regenerating epithelial cells
can spread and migrate (Toback, 1992; Bonventre, 2003). Healing
via focal ﬁbrotic scarring is also seen secondary to severe paren-
chymal injury, for instance in pyelonephritis or infarction, and serves
to maintain tissue integrity. Whilst ﬁbrosis is a normal sequel of
injury, it is thought that in CKD the normal wound healing re-
sponse fails to terminate (Liu, 2006;Wynn, 2010). Although the exact
mechanisms underlying this dysregulation are unclear, the result
is an excessive, inexorable ﬁbrogenic response and the expansion
of the extra-cellular matrix (ECM) gradually destroys normal tissue
structure (Eddy, 1996). The histopathology of renal ﬁbrosis fea-
tures excessive accumulation of ECM proteins within the
tubulointerstitial space and is accompanied by loss of the renal mi-
crovasculature, inﬁltration of mononuclear cells, tubular atrophy and
dilation (Fig. 1). The aberrant extracellular matrix is composed of
normal matrix proteins and proteoglycans as well as other matrix
proteins normally restricted to tubular basement membranes, such
as collagen IV and laminin (Vleming et al., 1995; Eddy, 1996).
In the normal kidney, interstitial ﬁbroblasts play a crucial role
in ECM homeostasis via their dual roles in the synthesis of ECM and
production of ECM degrading proteases (Strutz and Zeisberg, 2006).
In ﬁbrogenesis, these cells are believed to become activated and
undergo a phenotypic change to become myoﬁbroblasts. The in-
duction and proliferation of myoﬁbroblasts is probably a crucial event
in the initiation and progression of renal ﬁbrosis. Myoﬁbroblasts
possess qualities of both ﬁbroblasts and smooth muscle cells and
are considered the dominant ECM producing cells in organ ﬁbro-
sis (Prunotto et al., 2011; Lebleu et al., 2013). It is not possible to
differentiate these cells from ﬁbroblasts via light microscopy and
they are characterised by their expression of alpha smooth muscle
actin (α-SMA) and vimentin. Both vimentin and α-SMA expres-
sion increase within the kidney in naturally occurring feline CKD
and the expression of these cellular markers correlates with in-
creasing plasma creatinine concentration and kidney ﬁbronectin
deposition (Sawashima et al., 2000; Yabuki et al., 2010).
The precise origin of myoﬁbroblasts has historically been con-
troversial, and several cell types as well as resident ﬁbroblasts are
known to undergo phenotypic changes to ECM producing cells in
renal ﬁbrosis, including tubular epithelial cells, circulating ﬁbrocytes,
vascular pericytes, endothelial cells and glomerular podocytes (Kim
et al., 2013). The relative contribution of these cellular types to the
myoﬁbroblast pool is the focus of ongoing investigation. One recent
comprehensive analysis examining the relative contribution of
various cell types to the myoﬁbroblast lineage, using mice with ex-
perimentally induced obstructive renal disease, found that 50% of
the population arose from proliferation of resident ﬁbroblasts whilst
the remainder differentiated from bone marrow derived cells (35%),
endothelial cells (10%) and epithelial cells (5%) (Lebleu et al., 2013).
Myoﬁbroblast induction, proliferation and ECM production are
regulated by a number of local and circulating factors. These include
paracrine or autocrine growth factors, direct interaction with
leucocytes/macrophages, and environmental stimuli such as hypoxia
and hyperglycaemia (Qi et al., 2006). Recent studies have also
emphasised the importance of renal tubular epithelial cell damage
and altered epithelial–mesenchymal cell signalling in the activa-
tion of renal ﬁbroblasts towards the myoﬁbroblast type in CKD
(Prunotto et al., 2012; Moll et al., 2013).
Pro-ﬁbrotic mediators
Transforming growth factor beta (TGF-β)
The cytokine TGF-β is potentially the most important pro-
ﬁbrotic mediator responsible for myoﬁbroblast activation, appearing
to be a convergent pathway that integrates the effects of many other
ﬁbrogenic factors (Liu, 2006; Farris and Colvin, 2012). TGF-β1 is the
most abundant isoform and is synthesised by all cell types of the
kidney, with epithelial cells demonstrated to be the main source
in experimentally induced disease (Fukuda et al., 2001; Wu et al.,
2013). TGF-β is secreted as a latent precursor andmust undergo pro-
teolytic cleavage in order for the active form of the cytokine to be
liberated, which may be initiated directly by a variety of mol-
ecules including plasmin and reactive oxygen species (Annes et al.,
2003). Once activated, TGF-β exerts its subsequent effects by binding
to the TGF-β receptor II and regulating the transcription of target
genes (Wang et al., 2005). Production of TGF-β has been demon-
strated to be induced by a variety of stimuli, including the renin–
angiotensin–aldosterone system (Wolf, 2006), hypoxia (Orphanides
et al., 1997), proteinuria (Eddy and Giachelli, 1995), increased single
nephron glomerular ﬁltration rate (Rohatgi and Flores, 2010) and
oxidative stress (Shin et al., 2008).
TGF-β is upregulated in nearly all mammalian chronic kidney
diseases, and evidence from rodent models supports the hypoth-
esis that TGF-β signalling is central to the induction of kidney disease.
Mice overexpressing TGF-β develop interstitial ﬁbrosis (Koesters et al.,
2010) and downstream disruption of the TGF-β signalling pathway
has been demonstrated to ameliorate renal ﬁbrosis (Sato et al., 2003).
The proﬁbrotic effects of TGF-β include inducing the formation of
myoﬁbroblasts from various cell types in vitro, including ﬁbro-
blasts (Serini et al., 1998), pericytes (Wu et al., 2013) and potentially
also endothelial cells (He et al., 2013), although the relative signif-
icance of these ﬁndings in vivo is controversial. It directly stimulates
transcription of ECM genes in many renal cells, including tubular,
endothelial and mesangial cells (Border and Noble, 1993) and also
decreasesmatrix degradation (Edwards et al., 1987; Krag et al., 2005).
TGF-β1 signalling in tubular epithelial cells alone, independent of
myoﬁbroblasts, is suﬃcient to cause tubular injury, apoptosis and
accumulation of inﬂammatory cells (Gentle et al., 2013). As well as
direct effects, TGF-β also acts to stimulate cell proliferation and ECM
accumulation through downstream activation of the pro-ﬁbrotic
cytokine connective tissue growth factor (CTGF) (Grotendorst, 1997).
TFG-β (normalised to urinary creatinine) has been shown to be
present in increased concentrations in the urine of cats with
Fig. 1. Photomicrograph illustrating severe cortical interstitial ﬁbrosis and inﬂam-
mation in the kidney of a cat with CKD. Periodic acid-Schiff and haematoxylin.
Reprinted with permission from Veterinary Pathology, SAGE publications.
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naturally occurring CKD. One study found a signiﬁcant increase in
urine TGF-β1:urine creatinine ratio (TGF-β1:UCrR) in a group of 23
cats with CKD in comparison to a group of 13 healthy controls, whilst
documenting no difference in serum TGF-β1 concentrations (Arata
et al., 2005). Another study comparing 18 healthy cats to 26 with
CKD also demonstrated an increased TGFβ1:UCrR in cats with CKD,
and a positive correlation between TGF-β1:UCrR and serum cre-
atinine (Habenicht et al., 2013). These preliminary results suggest
urinary TGF-β1 may be useful as a biomarker of renal injury in CKD
and a potential tool for assessing response to therapeutic interven-
tions. However, a major disadvantage of feline studies to date is the
lack of concomitant histopathology with which to correlate these
ﬁndings. Furthermore, the relative value of the different forms of
TGF-β1 measured in feline urine and/or serum as biomarkers of
active renal pathology warrants further study.
Components of the renin–angiotensin–aldosterone system
The renin–angiotensin–aldosterone system (RAAS) is an endo-
crine pathway that plays an integral role in the homeostatic control
of arterial pressure, tissue perfusion and extracellular volume (Atlas,
2007) (Fig. 2). The RAAS is upregulated early in CKD (Siragy and
Carey, 2010) and plasma renin, aldosterone and angiotensins I and
II have been demonstrated to be increased in the circulation of cats
with experimentally induced CKD (Watanabe and Mishina, 2007).
Both systemic and intrarenal RAAS exist, and assessment of the sys-
temic RAAS alone does not necessarily indicate the state of the RAAS
system in the kidney. Angiotensin II in particular may be present
in much higher concentrations within the kidney than in the cir-
culation (Kobori et al., 2007).
The RAAS is a mediator of progressive renal injury via increas-
ing glomerular pressure and the subsequent ﬁltration of plasma
protein, but its components also have direct ﬁbroproliferative effects.
Angiotensin II, the primary active product of the RAAS, is believed
to be the most important via upregulation of TGF-β signalling and
pro-inﬂammatory gene transcription (Ruster and Wolf, 2011). As
well as TGF-β, angiotensin II also has the potential to induce a variety
of other pro-inﬂammatory and pro-ﬁbrotic mediators including CTGF
and endothelin 1 (Yokoi et al., 2001; Wolf et al., 2002). Aldoste-
rone and renin are also implicated as effectors of ﬁbrogenesis by
increasing TGF-β expression and production respectively (Sun et al.,
2000; Juknevicius et al., 2004; Huang et al., 2006). Aldosterone is
also believed to have TGF-β independent effects via stimulating pro-
duction of CTGF (Han et al., 2006).
Suppression of the RAAS via inhibition of angiotensin convert-
ing enzyme (ACE) has been demonstrated to ameliorate or halt renal
ﬁbrosis in several models of CKD (Ishidoya et al., 1996; Garber et al.,
1998; Mizuno et al., 1998), although conﬂicting reports exist (Turan
et al., 2003). Administration of ACE inhibitors to human patients with
a range of kidney diseases delays progression of CKD, indepen-
dent of their anti-hypertensive action (Maschio et al., 1996), but this
effect has not yet been demonstrated in cats. In clinical trials of ACE
inhibitors in cats with CKD, those receiving benazepril showed a
signiﬁcant reduction in proteinuria, but to date, no signiﬁcant sur-
vival beneﬁt (King et al, 2006; Mizutani et al., 2006; Watanabe and
Mishina, 2007). One study investigating the relationship between
the intra-renal expression of renin and angiotensin II and renal his-
topathology in cats found no relationship between their expression
and tubulointerstitial ﬁbrosis, although there were only 13 cats en-
rolled in this study (Mitani et al., 2013). The same study documented
a positive correlation between interstitial angiotensin II expres-
sion and ﬁbrosis in dogs, and thus it is possible that the intra-
renal RAAS is not as signiﬁcant a mediator of interstitial ﬁbrosis in
cats as it appears to be in other species.
Transglutaminase 2
Transglutaminase 2 (TG-2) is an ubiquitously expressed member
of the transglutaminase family of calcium dependent cross-linking
enzymes with important enzymatic and non-enzymatic functions
in the extracellular matrix (Belkin, 2011). The transamidase activ-
ity of TG-2 plays a role in extracellular matrix stabilisation by cross-
linking extracellular matrix proteins (Shweke et al., 2008; Iismaa
et al., 2009). This leads to increased ECM deposition and resis-
tance to ECM breakdown via proteolytic enzymes (Johnson et al.,
1999). In addition to its direct enzymatic effects TG-2 is involved
in cross-linking TGF-β1 to the ECM (Annes et al., 2003) and may
contribute to tissue ﬁbrosis via activation of TGF-β1 (Shweke et al.,
2008), as well as stimulating pro-inﬂammatory signalling (Kim et al.,
2010).
TG-2 has been linked to a variety of ﬁbrotic conditions affect-
ing the liver, lung, heart and kidney (Iismaa et al., 2009).
Experimental administration of TG-2 inhibitors to rodent models
of kidney disease decreases the severity of ﬁbrosis, implicating TG-2
as an active player in the progression of ﬁbrosis in CKD (Johnson
et al., 2007; Huang et al., 2009). A strong association between TG-2
expression and renal ﬁbrosis has been observed in rodent models
(Johnson et al., 1999), humans (Johnson, 2003) and recently also
Fig. 2. The renin–angiotensin–aldosterone system.
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in cats (Sánchez-Lara et al., 2013). In addition to histopathological
changes, extracellular TG-2 activity was also positively correlated
with plasma creatinine, urea and phosphate in cats in this study.
This dual correlation of TG-2 with histopathological evidence of ﬁ-
brosis and biochemical markers of disease severity suggests it may
be an ideal target for further investigation and a potential future
therapeutic target.
Endothelin 1
Endothelin 1 (ET-1) is a peptide produced in the heart, kidney,
central nervous system and posterior pituitary gland with varied
physiological roles throughout the body. Within the kidney it is re-
leased in response to activation of the RAAS (Kohno et al., 1992),
hypoxia (Hughes et al., 1996) and other pro-ﬁbrotic mediators such
as TGF-β (Schnermann et al., 1996). ET-1 acts as a potent vasocon-
strictor but also has a considerable pro-ﬁbrotic effect. Over-
expression of ET-1 results in development of interstitial ﬁbrosis in
transgenic mice (Hocher et al., 1997) and increased renal ET-1 ex-
pression has been demonstrated in human renal disease (Duan et al.,
1999; Nakamura et al., 2000) as well as experimental models of
kidney disease (Lebel et al., 2006). Pharmacological antagonism of
the ET-1 receptor is known to attenuate ﬁbrosis in rats with exper-
imentally induced kidney disease (Benigni et al., 1993; Ebihara et al.,
1997).
An increase in ET-1 mRNA expression in biopsied renal tissue
has been reported in one study of cats affected by renal failure
(Uchide and Saida, 2006). Conversely, in one recent analysis, plasma
and urinary ET-1 concentrations were not associated with plasma
creatinine concentration and tubular ET-1 expression was not as-
sociated with ﬁbrosis (Chakrabarti, 2012). Total ET-1 expressionmay
however be unrepresentative of this peptide’s true role in CKD. ET
receptors have been found to be upregulated in experimentally
induced acute kidney injury (Roubert et al., 1994), as well as in
human patients with polycystic kidney disease (Ong et al., 2003),
and it is possible that it is an increased sensitivity to ET-1 that leads
to pathological effects.
Factors involved in the progression of renal ﬁbrosis
The mechanisms behind continued and progressive ﬁbrotic
change in CKD are not completely understood. It is thought that the
intra-renal environment in CKD is signiﬁcantly pro-ﬁbrotic, leading
to continued production of pro-inﬂammatory and pro-ﬁbrotic
cytokines and the perpetuation of thewound healing response rather
than its resolution. The factors with the most inﬂuence on main-
taining this state and which have undergone the most investigation
to date are believed to be proteinuria, chronic inﬂammation, hypoxia,
ageing and hyperphosphataemia.
Proteinuria
The classical ‘hyperﬁltration theory’ postulates that as single
nephron glomerular ﬁltration rate increases in proportion to the
amount of renal tissue lost, plasma protein ﬁltration increases and
subsequent glomerular and tubular damage occurs, triggering further
ﬁbrosis and creating a vicious cycle (Hostetter et al., 1981). It is be-
lieved that excess protein within the glomerular ﬁltrate may have
intrinsic renal toxicity due to increased uptake by tubular cells and
accumulation of abnormal amounts of protein within the intersti-
tium. Protein overload has been associated with proximal tubular
cell apoptosis in experimentally induced renal disease (Tejera et al.,
2004) and proximal tubular cells subjected to protein overload
upregulate genes encoding for pro-inﬂammatory and pro-ﬁbrotic
mediators in vitro and in vivo (Eddy and Giachelli, 1995; Zoja et al.,
1999; Nakajima et al., 2002). These factors cause increased
inﬁltration of leukocytes in the protein-overloaded areas and chronic
inﬂammation results (Abbate et al., 1998). Proteinuria has been sug-
gested to be associated with increased ET-1 (Vlachojannis et al.,
2002), TGF-β (Eddy and Giachelli, 1995) and ACE expression (Largo
et al., 1999). Tubular protein overload is also believed to cause ep-
ithelial to mesenchymal transition of proximal tubular cells to
myoﬁbroblasts, thus contributing directly to the increase in ECM
producing cells that occurs in CKD (although this is of debateable
signiﬁcance) (Abbate et al., 2002).
Proteinuria is an established negative prognostic factor in feline
CKD. Urine protein to creatinine ratio (UPC) is correlatedwith plasma
creatinine concentration and independently associated with shorter
survival times (Syme et al., 2006). In one study evaluating predic-
tors of the development of azotaemia in cats, proteinuria at
presentation was signiﬁcantly associated with the development of
azotaemia and alongside creatinine was the only signiﬁcant pre-
dictor in a multivariable analysis (Jepson et al., 2009). UPC has also
been shown to be a signiﬁcant and independent risk factor for a >25%
increase in plasma creatinine concentration within 12 months of
diagnosis of CKD (Chakrabarti et al., 2012a) and to be positively cor-
relatedwith post-mortem interstitial ﬁbrosis score (Chakrabarti et al.,
2013). Despite these associations, it is not yet possible to infer a
causal role for proteinuria in feline CKD and renal ﬁbrosis as these
ﬁndings may just reﬂect decreased tubular uptake capacity in dis-
eased kidneys. It is also possible that glomerular disease, which
proteinuria is characteristically associated with, represents a more
progressive form of CKD and is itself linked with increased
ﬁbrosis.
Inﬂammation
Tubulointerstitial inﬁltration of lymphocytes and macrophages
is an early feature of CKD and may be induced by proteinuria, re-
active oxygen species generation and upregulation of angiotensin
II (Rodriguez-Iturbe et al., 2001). Regardless of the initial cause,
chronic renal inﬂammation is believed to play a critical role in the
pathophysiology of CKD and the perpetuation of renal ﬁbrosis
(Rodriguez-Iturbe and Garcia Garcia, 2010). Depletion of inﬂam-
matory cells, such as macrophages and T-cells, has been
demonstrated to ameliorate progression of tubulointerstitial ﬁbro-
sis in rodent models of kidney disease (Ko et al., 2008) (Tapmeier
et al., 2010). A variety of agents which interfere with the inﬂam-
matory process have also demonstrated the ability to prevent
inﬂammatory cell inﬁltration and progression of renal ﬁbrosis in
experimental models, including the immunosuppressive drug
mycophenolate mofetil (Romero et al., 1999), chemokine receptor
CCR1 antagonists (Vielhauer et al., 2004), and inhibitors of the pro-
inﬂammatory NF-κB pathway (Tamada et al., 2003).
Chronic inﬂammation sustains the production of pro-ﬁbrotic
growth factors and chemokines from activated epithelial and en-
dothelial cells, as well as inﬁltrating leukocytes. Macrophages have
been hypothesised to promote ﬁbrogenesis via TGF-β signalling (Ko
et al., 2008) but have also been demonstrated to switch from a pro-
inﬂammatory to a suppressive phenotype after initial kidney damage
(Lee et al., 2011), and their true role in renal injury and disease is
likely to be complex. T-cells are believed to modulate myoﬁbroblast
activation, either via direct effects on resident ﬁbroblasts or via in-
ducing macrophages/tubular cells to produce proﬁbrotic cytokines/
growth factors (Nikolic-Paterson, 2010). Inﬂammatory cells are also
able to differentiate into myoﬁbroblasts and may contribute direct-
ly to ECM accumulation via this pathway (Jabs et al., 2005).
In cats, tubulointerstitial ﬁbrosis is associated with inﬁltration
of lymphocytes and plasma cells (DiBartola et al., 1987) and one
recent study found a moderate correlation between the degree of
inﬂammation and tubulointersitial ﬁbrosis in feline CKD (Chakrabarti
et al., 2013). The chemokine IL-8, a neutrophil chemotactic factor
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which is released by leukocytes and endothelial cells in response
to inﬂammation, has also been shown to be present in increased
concentrations in the urine of cats with CKD (Habenicht et al., 2013).
Hypoxia
Chronic hypoxia of the renal tubulointerstitium has been
hypothesised to be the ﬁnal common pathway by which CKD pro-
gresses to end stage renal disease (Mimura and Nangaku, 2010). This
is supported by evidence from experimental models of CKD where
tubular hypoxia has been demonstrated to precede histopathologi-
cal evidence of kidney damage, suggesting a causal relationship
(Manotham et al., 2004).
Although the kidney receives 25% of cardiac output, far in excess
of metabolic requirements, it is intrinsically susceptible to hypoxia
due to the arteriovenous shunting of oxygen which results in the
extraction of no more than 10% of the oxygen delivered by the renal
artery (Evans et al., 2008). The renal cortex is perfused at a sub-
stantially greater rate than the outer and inner medulla, but tubular
epithelial cells are especially vulnerable to hypoxic injury due to
their high metabolic rate and reliance on aerobic metabolism
(Epstein, 1997). In CKD, a series of factors lead to the develop-
ment of a hypoxic state. The oxygen consumption of remnant
nephrons within the diseased kidney is up to three times the oxygen
requirement of normal nephrons due to the up-regulated meta-
bolic activity of tubular cells (Harris et al., 1988). The capability of
the cardiovascular system to meet this demand is hindered by the
loss of peritubular capillaries associated with tubulointerstitial ﬁ-
brosis (Choi et al., 2000), RAAS mediated vasoconstriction (Nangaku
and Fujita, 2008) and the increased diffusion distance between cap-
illaries and tubular cells created by the expansion of the ECM,
resulting in tissue hypoxia.
Hypoxia acts to drive ﬁbrogenesis through multiple pathways.
Tubular cells exposed to mild hypoxia have been demonstrated to
undergo transition into myoﬁbroblasts (Xie et al., 2001; Zell et al.,
2013) and exposure to severe hypoxia can result in apoptosis (Khan
et al., 1999). Hypoxia also has direct effects on renal ﬁbroblasts, re-
sulting in increased matrix production, decreased matrix turnover
and production of pro-ﬁbrotic mediators (Norman et al., 2000).
Hypoxia may also act as a stimulus for the inﬂammatory response
via the recruitment of inﬂammatory cells (Kong et al., 2004).
In cats high urinary vascular endothelial growth factor (VEG-
F), a marker of hypoxia within tissues, has been associated with
shorter survival and progression of azotaemia, suggesting renal
hypoxia is associated with progression in feline CKD (Chakrabarti
et al., 2012b). However another recent study found that urinary
VEG-F was signiﬁcantly lower in cats with CKD than normal cats,
so the signiﬁcance of this marker and the role of hypoxia in feline
CKD remains undetermined (Habenicht et al., 2013).
Ageing
The ageing kidney is characterised by a number of progressive
morphological changes, including loss of renal mass, glomerulo-
sclerosis and interstitial ﬁbrosis (Pannarale et al., 2010). The amount
of ECM present within the renal interstitium increases signiﬁ-
cantly with age (Abrass et al., 1995; Thomas et al., 1998), although
this change differs substantially from the interstitial ﬁbrosis of CKD
with respect to the ECM composition. In cats, there is evidence that
tubulointerstitial inﬂammation begins early in life and that these
histopathological changes increase signiﬁcantly with age (Lawler
et al., 2006). The mechanisms behind age-related ﬁbrogenesis are
multifactorial and include increased inﬂammatory cell inﬁltra-
tion, increased myoﬁbroblast activation, increased susceptibility to
apoptosis and adverse haemodynamic changes in aged kidneys
(Thomas et al., 1998). The expression of several pro-regenerative
growth factors, including epidermal growth factor (EGF) (Chou et al.,
1997) and insulin like growth factor (IGF-1) (Chou et al., 1997), also
decreases with age whilst there is an increase in pro-ﬁbrotic TGF-β
signalling (Ding et al., 2001).
The ageing process compromises the ability of the kidney to heal
after acute or chronic injury, with various alterations contributing
towards perpetuation of the chronic inﬂammatory response and sub-
sequent ﬁbrosis rather than resolution of the reparative phase
(Pannarale et al., 2010). Studies utilising experimental models of
renal injury have revealed an age dependent decline in the prolif-
erative potential of tubular epithelial cells (Schmitt et al., 2008)
believed to be associated with cellular senescence, the phenome-
nonwhere cells lose the ability to divide or replicate and thus cannot
contribute to active repair. Cellular senescence is associated with
shorter length of telomeres, the structures which protect the chro-
mosome ends from degradation (Bodnar et al., 1998), and is
characterised by morphological changes and altered cellular func-
tion. Markers of cellular senescence have been associated with renal
ﬁbrosis in experimental rodent models of renal disease as well as
in humans (Melk et al., 2009; Braun et al., 2012) and, together with
shortened telomere length, have also recently been linkedwith feline
CKD (Quimby et al., 2013).
Hyperphosphataemia
Whilst elevated plasma phosphate may be a consequence of pro-
gressive loss of renal function, phosphate has been demonstrated
to be associated with progression of renal disease independent of
GFR in human studies (Zoccali et al., 2011), suggesting that phos-
phate might be causally implicated in renal disease progression.
It has long been recognised that increased plasma phosphate is
associated with pathological changes within the kidney, with pub-
lications dating back to 1935 noting dramatic histological changes,
including necrosis of the convoluted tubules, calciﬁcation and an
increase in connective tissue, in normal animals fed high phos-
phate diets (Mackay and Oliver, 1935; Craig, 1959; Haut et al., 1980).
Feeding of a phosphate restricted diet to cats with experimentally
induced renal disease has been demonstrated to prevent histologi-
cal damage in comparison with cats fed a high phosphate diet, the
kidneys of which developed calciﬁcation, ﬁbrosis and mono-
nuclear cell inﬁltration (Ross et al., 1982). Initially there was
controversy regarding these ﬁndings, as diets low in phosphate are
also intrinsically associated with protein restriction (Laouari et al.,
1982). Subsequent studies have supported the fact that phos-
phate restriction reduces renal injury in experimental models of
disease independent of protein intake (Lumlertgul et al., 1986; Finco
et al., 1992; Koizumi et al., 2002), whereas the beneﬁt of protein
restriction on the progression of CKD is controversial.
Themechanism for the detrimental effect of hyperphosphataemia
on kidney tissue is unknown. The most common explanation for
the deleterious effects of phosphate in these models is phosphate-
induced calciﬁcation of the renal parenchyma resulting in an
inﬂammatory and ﬁbrotic response. There is evidence from human
CKD and experimental models that hyperphosphataemia is asso-
ciatedwith nephrocalcinosis and subsequent functional deterioration
(Gimenez et al., 1987; Cozzolino et al., 2002). However, in the only
published work relating kidney lesions to clinicopathologic vari-
ables in cats with naturally occurring CKD, plasma phosphate was
associated with interstitial ﬁbrosis but was not associated with
tubular mineralisation (Chakrabarti et al., 2013). This suggests that
the association between phosphate and progressive kidney ﬁbro-
sis in cats may not involve parenchymal mineralisation but occurs
via another mechanism.
Several alternative mechanisms have been proposed. In pa-
tients with CKD and other syndromes which cause elevated plasma
phosphate, hyperphosphataemia is associated with vascular
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calciﬁcation and stiffness (Kendrick and Chonchol, 2011).
Hyperphosphataemia may also interfere with the function of, and
even directly damage, the microvascular endothelium within the
kidney (Kang et al., 2002; Di Marco et al., 2008; Shuto et al., 2009).
These negative haemodynamic consequences may lead to isch-
aemia and hypoxia, and hence progressive ﬁbrotic change. Phosphate
may have direct effects on epithelial and mesenchymal cells within
the kidney, leading to a pro-ﬁbrotic state. Increased extracellular
phosphate has wide ranging effects on cellular physiology (Camalier
et al., 2013) and has been associated with apoptosis (Ohnishi and
Razzaque, 2010), cellular senescence (Takemura et al., 2011) and
oxidative stress (Kuro-o, 2010). Increasing concentrations of extra-
cellular phosphate have also been demonstrated to increase the
production of ECM and pro-ﬁbrotic molecules by ﬁbroblasts (Beck
et al., 2000; Chen et al., 2012). Alternatively, phosphate may act in-
directly via effects on the RAAS. Increased plasma phosphate may
result in increased ACE expression within the kidney (Eraranta et al.,
2012), and high plasma phosphate was associated with attenua-
tion of the renoprotective effects of ACE inhibition in one human
epidemiological study (Zoccali et al., 2011).
Conclusions
Halting or slowing the insidious progression of renal ﬁbrosis is
an ideal treatment target for preventing deterioration of CKD to end
stage kidney disease, as it is the ﬁnal convergent process of a variety
of renal pathologies. Several of the mechanisms reviewed in this
article are already targeted in the treatment recommendations for
CKD in cats published by the International Renal Interest Society.1
Cats diagnosed with stage 2 CKD and above with urine protein to
creatinine ratio persistently higher than 0.4 should be treated with
anti-proteinuric measures, which may include dietary protein re-
striction and pharmacological ACE or angiotensin II inhibition. The
IRIS guidelines also include target reference ranges for plasma phos-
phate for cats in difference stages of CKD and a reduction of
phosphate intake via dietary restriction, often in combination with
a dietary phosphate binder, is recommended to maintain plasma
phosphate within these ranges (Table 1). The future promises further
therapeutics targeting the progression of renal ﬁbrosis. A number
of inhibitors of the TGF-β signalling system have been trialled ex-
perimentally and there is ongoing research into pharmacological
manipulation of the kidney’s response to hypoxia. It is hoped that
further elucidation of the role played by these potential media-
tors of injury will lead to novel therapeutic targets, and better clinical
outcomes, in the treatment of feline CKD.
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